C
Claire Roberts
Researcher at GW Pharmaceuticals
Publications - 10
Citations - 1518
Claire Roberts is an academic researcher from GW Pharmaceuticals. The author has contributed to research in topics: Cannabidiol & Lennox–Gastaut syndrome. The author has an hindex of 5, co-authored 9 publications receiving 1037 citations.
Papers
More filters
Journal ArticleDOI
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
Orrin Devinsky,Anup D. Patel,J. Helen Cross,Vicente Villanueva,Elaine C. Wirrell,Michael Privitera,Sam M. Greenwood,Claire Roberts,Daniel Checketts,Kevan E. VanLandingham,Sameer M. Zuberi +10 more
TL;DR: Among children and adults with the Lennox–Gastaut syndrome, the addition of cannabidiol at a dose of 10 mg or 20 mg per kilogram per day to a conventional antiepileptic regimen resulted in greater reductions in the frequency of drop seizures than placebo.
Journal ArticleDOI
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
Elizabeth A. Thiele,Eric D. Marsh,Jacqueline A French,Maria Mazurkiewicz-Bełdzińska,Selim R Benbadis,Charuta Joshi,Paul D Lyons,Adam Taylor,Claire Roberts,Kenneth W. Sommerville,Kenneth W. Sommerville,Boudewjin Gunning,Jacek Gawlowicz,Pawel Lisewski,Maria Mazurkiewicz Beldzinska,Krystyna Mitosek Szewczyk,Barbara Steinborn,Marta Zolnowska,Elaine Hughes,Ailsa McLellan,Selim R. Benbadis,Michael A. Ciliberto,Gary G. Clark,Dennis J. Dlugos,Francis Filloux,Robert Flamini,Jacqueline A. French,Michael Frost,Sheryl R. Haut,Siddarth Kapoor,Sudha Kilaru Kessler,Linda Laux,Paul D. Lyons,Eric D. Marsh,David Moore,Richard P. Morse,Venkatesh Nagaraddi,William E. Rosenfeld,Laurie E. Seltzer,Renée A. Shellhaas,Joseph Sullivan,Elizabeth A. Thiele,Liu Lin Thio,David Wang,Angus A. Wilfong +44 more
TL;DR: Add-on cannabidiol is efficacious for the treatment of patients with drop seizures associated with Lennox-Gastaut syndrome and is generally well tolerated.
Journal ArticleDOI
Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial
Orrin Devinsky,Rima Nabbout,Ian Miller,Linda Laux,Marta Zolnowska,Stephen Wright,Claire Roberts +6 more
TL;DR: An interim analysis of the safety, efficacy, and patient‐reported outcomes from GWPCARE5 is presented.
Journal ArticleDOI
Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study
Elizabeth A. Thiele,Eric D. Marsh,Maria Mazurkiewicz-Bełdzińska,Jonathan J. Halford,Boudewijn Gunning,Orrin Devinsky,Daniel Checketts,Claire Roberts +7 more
TL;DR: An interim analysis of the safety, efficacy, and patient‐reported outcomes from the OLE study evaluating the long‐term safety and efficacy of CBD is presented.
Journal ArticleDOI
The AHEAD 3–45 Study: Design of a prevention trial for Alzheimer’s disease
Michael S. Rafii,Reisa A. Sperling,Michael C. Donohue,Jin Zhou,Claire Roberts,Michael C Irizarry,Shobha Dhadda,Gopalan Sethuraman,Lynn D. Kramer,Chad J. Swanson,David JianJun Li,Stephen Krause,Robert A. Rissman,Sarah Walter,Rema Raman,Keith A. Johnson,Paul S. Aisen +16 more
TL;DR: The AHEAD 3-45 Study will test whether with lecanemab (BAN2401) can slow the accumulation of tau and prevent the cognitive decline associated with AD during its preclinical stage, and is the first secondary prevention trial to employ plasma-based biomarkers to accelerate the screening process and potentially substantially reduce the number of screening PET scans.